SWGH.F Stock Overview
Together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Sawai Group Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥40.20 |
| 52 Week High | JP¥41.43 |
| 52 Week Low | JP¥38.18 |
| Beta | 0.20 |
| 1 Month Change | 0% |
| 3 Month Change | -2.97% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -26.72% |
| Change since IPO | 62.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| SWGH.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | -2.1% |
| 1Y | n/a | 2.2% | 21.3% |
Return vs Industry: Insufficient data to determine how SWGH.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SWGH.F performed against the US Market.
Price Volatility
| SWGH.F volatility | |
|---|---|
| SWGH.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SWGH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SWGH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | 3,482 | Mitsuo Sawai | www.sawaigroup.holdings |
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacturing, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and anus, chemotherapeutic and antineoplastic agents, respiratory system, etc., as well as vitamin preparations. It sells its generic drugs through distributors, wholesalers, and retailers in Japan and the United States.
Sawai Group Holdings Co., Ltd. Fundamentals Summary
| SWGH.F fundamental statistics | |
|---|---|
| Market cap | US$1.79b |
| Earnings (TTM) | US$123.66m |
| Revenue (TTM) | US$1.17b |
14.4x
P/E Ratio1.5x
P/S RatioIs SWGH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SWGH.F income statement (TTM) | |
|---|---|
| Revenue | JP¥168.20b |
| Cost of Revenue | JP¥116.03b |
| Gross Profit | JP¥52.17b |
| Other Expenses | JP¥34.41b |
| Earnings | JP¥17.76b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 11, 2024
| Earnings per share (EPS) | 426.75 |
| Gross Margin | 31.02% |
| Net Profit Margin | 10.56% |
| Debt/Equity Ratio | 41.4% |
How did SWGH.F perform over the long term?
See historical performance and comparisonDividends
2.6%
Current Dividend Yield32%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/23 08:45 |
| End of Day Share Price | 2024/06/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sawai Group Holdings Co., Ltd. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |